Aspirin for Exercise in Multiple Sclerosis (ASPIRE) (ASPIRE)
Aspirin for Exercise in Multiple Sclerosis (ASPIRE): A Double-Blind RCT of Aspirin or Acetaminophen Pretreatment to Improve Exercise Performance in Multiple Sclerosis (MS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of relapsing-remitting MS
- self-reported heat-sensitivity to exercise
- Expanded Disability Status Scale (EDSS) total score ≤ 6.0
- exacerbation-free (and no use of corticosteroids) for 6 weeks prior
- BMI ≤ 40
Exclusion Criteria:
- prior history of significant head injury, stroke, or other neurological disease/disorder
- current daily use of antipyretics or pain medication
- currently in a major depressive episode
- vascular disease of the legs, uncontrolled high blood pressure
- uncontrolled diabetes mellitus or problem with blood sugar levels
- contraindications to aspirin use (history of confirmed peptic ulcer, gastrointestinal or severe gynecological bleeding)
- tarry stool or known fecal occult blood
- uncontrolled syndrome of asthma, rhinitis, or nasal polyps
- contraindications to acetaminophen use (severe active hepatic disease, Hepatitis C Virus)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Aspirin
Aspirin 650 mg capsule by mouth, single dose
|
A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
Other Names:
|
|
Active Comparator: Acetaminophen
Acetaminophen 650 mg capsule by mouth, single dose
|
A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.
Other Names:
|
|
Placebo Comparator: Placebo
Placebo 650 mg capsule by mouth, single dose
|
A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time-to-exhaustion
Time Frame: from start of exercise test until self-reported exhaustion, up to 30 minutes
|
Duration of time exercising before reaching peak exertion, defined as cadence drop below 40 revolutions per minute (RPM) for >/= 5 seconds, or patient reaches volitional exhaustion in accordance with American Thoracic Society standard test termination criteria.
|
from start of exercise test until self-reported exhaustion, up to 30 minutes
|
|
Exercise-induced Body Temperature Change
Time Frame: from start of exercise test until self-reported exhaustion, up to 30 minutes
|
Change in body temperature from pre- to post- maximal exercise test.
|
from start of exercise test until self-reported exhaustion, up to 30 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exercise-induced body temperature increase
Time Frame: from start of exercise test until self-reported exhaustion, up to 30 minutes
|
Change in body temperature from pre- to post- maximal exercise test
|
from start of exercise test until self-reported exhaustion, up to 30 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Victoria M Leavitt, PhD, Columbia University
Publications and helpful links
General Publications
- Leavitt VM, Blanchard AR, Guo CY, Gelernt E, Sumowski JF, Stein J. Aspirin is an effective pretreatment for exercise in multiple sclerosis: A double-blind randomized controlled pilot trial. Mult Scler. 2018 Oct;24(11):1511-1513. doi: 10.1177/1352458517739138. Epub 2017 Oct 27.
- Kever A, Nelson KE, Aguerre IM, Riley CS, Boehme A, Lee NW, Strauss Farber R, Levin SN, Stein J, Leavitt VM. ASPIRE trial: study protocol for a double-blind randomised controlled trial of aspirin for overheating during exercise in multiple sclerosis. BMJ Open. 2020 Nov 14;10(11):e039691. doi: 10.1136/bmjopen-2020-039691.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
- Acetaminophen
Other Study ID Numbers
Other Study ID Numbers
- AAAS2529
- 1R21HD091836-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.